| __timestamp | Bausch Health Companies Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 79529000 |
| Thursday, January 1, 2015 | 2682700000 | 91224000 |
| Friday, January 1, 2016 | 2810000000 | 102413000 |
| Sunday, January 1, 2017 | 2582000000 | 146987000 |
| Monday, January 1, 2018 | 2473000000 | 213695000 |
| Tuesday, January 1, 2019 | 2554000000 | 342000000 |
| Wednesday, January 1, 2020 | 2367000000 | 661000000 |
| Friday, January 1, 2021 | 2624000000 | 1283000000 |
| Saturday, January 1, 2022 | 2625000000 | 2676000000 |
| Sunday, January 1, 2023 | 2917000000 | 3297000000 |
| Monday, January 1, 2024 | 3790000000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Bausch Health Companies Inc. and Genmab A/S have showcased contrasting trajectories in their SG&A spending.
From 2014 to 2023, Bausch Health's SG&A expenses have seen a steady increase, peaking at approximately $2.9 billion in 2023. This represents a growth of about 44% from their 2014 levels. In contrast, Genmab A/S has experienced a dramatic rise, with SG&A expenses surging from a modest $80 million in 2014 to nearly $3.3 billion in 2023, marking an astonishing increase of over 4,000%.
This divergence highlights the strategic differences between the two companies, with Genmab A/S aggressively expanding its operational footprint, while Bausch Health maintains a more consistent approach.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc. Trends and Insights
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Bausch Health Companies Inc. or Evotec SE: Who Manages SG&A Costs Better?